Source: BioPharma-Reporter

Purolite: Purolite and Repligen to commercially launch novel CH1 affinity resin

Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.

Read full article »
Est. Annual Revenue
$100-500M
Est. Employees
1.0-5.0K
Steve Brodie's photo - President & CEO of Purolite

President & CEO

Steve Brodie

CEO Approval Rating

70/100

Read more